Apply

The life sciences industry has seen a lot of change in recent years, driven by new technologies, partnerships, and shifts in the market. The pandemic accelerated development in many areas but also presented challenges, from increased costs to more stringent regulations and supply chain disruptions. The industry is moving into a next era and has started to focus again on achieving long-term growth. 

The industry remains under pressure to bring new products and therapies to the patient, that provide real value in a highly competitive market. Companies have made some radical changes in their product strategy, divesting their commercial branches and placing their bets on becoming the leaders in oncology, neurosciences and immunology.

In this article, we investigate the key trends that will influence the sector in 2025, and companies can take advantage of technological advancements to better meet the growing demand for healthcare and medicines across the world. Apart from the continued pressure on drug development and the focus on patient value and centricity, 4 key topics will dictate the course of industry.

Precision Medicine

The goal of precision medicine, also known as personalized medicine, is to provide tailor-made prevention and treatment strategies for patients by taking into consideration their genetic makeup. Precision medicine has become one of the most recent emerging trends driven by scientific breakthroughs in new targeted therapies and genomics combined with the rise of AI technology required to process huge data volumes on patients. Companies like Novartis and Legend biotech have been working on CAR-T cell therapies (Chimeric Antigen Receptor T-cell therapy), a technology where the body’s immune cells are programmed to recognize and kill cancer cells. 

Novo Nordisk, known for their Ozempic treatment, has started to customize their diabetes treatments based on the genetic profiles of patients. Apart from these examples, precision medicine has the potential to transform the prevention and treatments of autoimmune disorders such as rheumatoid arthritis and neurological or cardiovascular diseases.

Precision Medicine.jpg

Focus on Sustainability

Sustainability has become a growing focus and strategic priority for life sciences companies.

This shift has mainly been driven by increasing consumer concerns about the environmental and social responsibility of the life sciences industry and regulatory demands. Life Sciences companies are implementing strategies to reduce the environmental footprint, mainly in manufacturing and their supply chain, optimizing waste management and exploring green chemistry for drug development. 

Next to ensuring a greener supply chain and manufacturing processes, companies are taking an increasing responsibility over the entire life cycle of their products, from design to end-of-life disposal and recycling and assessing the environmental impact on product. 

This is called product life-cycle management. Next to the reduction of their carbon emissions, industry is more and more committed to taking their social responsibility, advancing global health equity, access to medicines in underserved regions (e.g. vaccine donations, collaborations with NGO’s and differential pricing strategies). and helping to address the world’s toughest health challenges.

iStock-483205433.jpg

Integration of Artificial Intelligence

As in all industries, Artificial intelligence is set to play a major role in reshaping the industry across the entire value chain. In R&D, AI has the potential to speed up drug discovery by analyzing large datasets which will allow us to identify drug targets much faster using machine learning. In clinical trials, Ai allows them to recruit the right patients, predict trial outcomes and optimize study designs, helping pharmaceutical companies to save time and reduce costs. 

In manufacturing, AI will help to improve production processes, monitor quality and predict when maintenance of equipment is needed. When it comes to healthcare, AI-powered algorithms can analyze medical data, such as imaging, patients records and genetic information to detect diseases at the earliest stage. Companies such as Sanofi have gone “all in” on artificial intelligence and data sciences to speed breakthroughs for patients and aims to become the first pharma company to be powered by AI at scale. 

Selecting the right use cases in line with the desired business outcomes will be key. It is, however, important to note that the health authorities such as the FDA and EMA have not yet issued clear regulations and guidelines on the use of Artificial intelligence. Such guidelines will further bring clarity to the industry and accelerate the adoption of the technology at larger scale.

AI.png
ai 2.png

Digital Transformation in Manufacturing

The Life Sciences industry is finally embracing the digital revolution at full force. Pharmaceutical companies are finally turning to advanced tools to drive production efficiency and product yield. Enterprise resource planning (ERP) tools such as the latest version of SAP, S/4HANA, and manufacturing execution systems (MES) allow to streamline production processes, improve data visibility and allow real-time decision-making across the pharmaceutical supply chain. Other emerging technologies such as digital twins, a technology where virtual representations of physical assets are created, allow companies to simulate, monitor and optimize operations in real time. Next to that, technologies such as Internet-of-things (IoT)-enabled devices for predictive maintenance, and cloud-based supply chain platforms, are driving greater operational agility and compliance with global regulations.

Digital Transformation in Manufacturing.png

Evolving Regulatory Landscape

The regulatory landscape is evolving rapidly to keep up with the growing role of data, AI and sustainability. The FDA and EMA are formulating new guidelines to address the environmental impact and push for a greener industry. At the same time, advancements in AI are changing the way how companies develop drugs, conduct their clinical trials and run their supply chain. Companies will need to adopt these technologies keeping in mind the importance of data security, transparency and ethical use of AI. To conclude, the industry is aiming to further standardize and streamline requirements for drug development and approval across regions, a process called regulatory harmonization to accelerate market approvals and access to medicines.

AI.jpg

When looking into 2025, the life sciences industry is set to undergo significant changes driven by the advancements made in technology and the quest for a greener industry. Pharmaceutical companies will need to balance the implementation of these new technologies with continued economic pressures we have seen in 2023 and 2024 and regulatory requirements. To conclude, we believe that the life sciences industry is set for growth again following the post-covid consolidation. 

We are convinced that our portfolio of services for life sciences is well positioned to support the industry in terms of the challenges that lie ahead.

Picture6.png